Ros1-positive Non-small Cell Lung Cancer

• CLINICAL_TRIALS research · 2026-02-17
  Clinical Trial Update: Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

  Expanded access program for Zidesamtinib (NVL-520) in patients with advanced ROS1-positive solid tumors, including ROS1-positive non-small c…

• CLINICAL_TRIALS research · 2025-06-12
  Clinical Trial Update: Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer [Phase 2]

  A phase 2 neoadjuvant trial of WX-0593 for resectable ALK-positive or ROS1-positive non-small cell lung cancer is currently recruiting.

• FDA approval · 2023-10-20
  FDA Approved: ROZLYTREK — Original Application (Genentech, Inc.)

  Rozlytrek (entrectinib) received FDA approval in an original application for the treatment of NTRK gene fusion-positive solid tumors and ROS…

• FDA approval · 2023-08-31
  FDA Approved: ROZLYTREK — Supplemental Application (Genentech, Inc.)

  The FDA approved a supplemental application for Rozlytrek (entrectinib) submitted by Genentech, expanding its labeling.

• FDA approval · 2023-06-16
  FDA Approved: ROZLYTREK — Supplemental Application (Genentech, Inc.)

  The FDA approved a supplemental application for Rozlytrek (entrectinib) submitted by Genentech, Inc.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2013-09-13
  FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

  The FDA approved a supplemental application for XALKORI (crizotinib) submitted by Pfizer Laboratories Div Pfizer Inc.

• FDA approval · 2013-02-28
  FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

  FDA approved a supplemental application for XALKORI (crizotinib) from Pfizer Laboratories Div Pfizer Inc.